Yazar "Ergulen, A." seçeneğine göre listele
Listeleniyor 1 - 10 / 10
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The accuracy of OSEM and FBP reconstruction algorithm for the determination of the thyroid volume: A fantom study(Springer, 2007) Ergulen, A.; Durmus-Altun, G.; Ustun, F.; Erol, S.; Cildavil, S.; Berkarda, S.[Abstract Not Available]Öğe Experimental high dose radioactive I-131 ablation model in guinea pig(Springer, 2009) Torun, N.; Ergulen, A.; Dirlik, B.; Durmus-Altun, G.[Abstract Not Available]Öğe Exposure Dose Rates and Radiation Safety of Clinical Personal while Nursing Patients who Underwent Bone Scintigraphy(Springer, 2005) Yuksel, M.; Ergulen, A.; Yigitbasi, O. N.[Abstract Not Available]Öğe The histopathologic comparison of the protective effects of L-Carnitine and amifostine against high-dose radioiodine therapy -induced lacrimal gland damage in the guinea pig(Springer, 2009) Durmus-Altun, G.; Ozdil-Muratli, A.; Torun, N.; Ergulen, A.; Ustun, F.; Altaner, S.[Abstract Not Available]Öğe Improving the quality of Technetium-99m-labelled red blood cell SPECT imaging by OSEM reconstruction(Springer, 2005) Durmus-Altun, G.; Bedel, D.; Ustun, F.; Ergulen, A.; Berkarda, S.[Abstract Not Available]Öğe Predictive value of dual time point imaging differentiation between malign and benign pancreatic lesions, Preliminary results(Springer, 2014) Ustun, F.; Ergulen, A.; Altun, G. Durmus[Abstract Not Available]Öğe Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study(Lithographia, 2012) Aktoz, T.; Durmus-Altun, G.; Usta, U.; Torun, N.; Ergulen, A.; Atakan, I. H.Background: Ablative radioiodine-131 (I-131) therapy is used in the standart treatment procedure of thyroid carcinoma and procedures using I-131 represent the majority of Nuclear Medicine therapeutic procedures. The principal route of I-131 excretion after the administration of I-131 is the urine. Amifostine is an organic thiophosphate ester prodrug and the kidney concentrations of the active metabolite WR-1065 are about 100 times higher than tumour concentrations. To our knowledge, there is no published data in literature presenting acute effect of radioiodine on renal tissue during high dose I-131 radioiodine treatment (RIT). Additionally, it is not known whether amifostine takes role in this process. Materials and methods: In this study, 50 healthy female Wistar albino rats, weighing 200-250 g and averaging 16 weeks old were utilised. The rats were randomly divided into ten groups. 1-Sham group (n=5), 2-Amifostine group (n=5): rats pretreated with 1 cc amifostine (200 mg/kg) by intraperitoneal injection, 3- Radioactive iodine first day group (RI-1) (n=5): rats treated with 1 cc oral 185 MBq radioactive iodine-131 and sacrification performed after 1st day, 4- Amifostine + Radioactive iodine first day group (A+RI-1) (n=5): rats pretreated with amifostine (200 mg/kg) by intraperitoneal injection and rats treated with 5mCi radioactive iodine-131 and sacrification performed after 1st day. 5- Radioactive iodine third day group (RI-3) (n=5), 6- Amifostine + Radioactive iodine third day group (A+RI-3) (n=5), 7- Radioactive iodine fifth day group (RI-5) (n=5), 8- Amifostine + Radioactive iodine fifth day group (A+RI-5) (n=5), 9- Radioactive iodine seventh day group (RI-7) (n=5) and 10- Amifostine + Radioactive iodine seventh day group (A+RI-7) (n=5). The renal cast formation and tubular damage are evaluated by a pathologist in a blinded manner. Results: Ablative radioiodine-131 therapy induced renal tubular damage was significantly higher in the radioactive iodine fifth day group (RI-5) when compared with the Sham group (p=0.01) and Amifostine group (p=0.01). Conclusions: A marked ablative radioiodine-131 induced renal toxicity was seen at fifth day of the therapy after a single RIT application and the main histopathological change was tubular damage. Amifostine have protective effects against ablative radioiodine-131 therapy and this effect is significant at fifth day of the therapy. Hippokratia. 2012; 16 (1): 4045Öğe The relation of radioiodine uptake and TSH level on non-thyroidal tissues(Springer, 2008) Torun, N.; Ergulen, A.; Durmus-Altun, G.[Abstract Not Available]Öğe Technologist Radiation Exposure in Routine Clinical Practice with I-131 Administration for Ablation of Thyroid Cancer(Springer, 2015) Ergulen, A.; Ustun, F.; Yigitbasi, O. N.; Durmus-Altun, G.[Abstract Not Available]Öğe Use of ordered-subsets expectation maximization (OSEM) for lesion detection and localization in Tc-99m DMSA SPECT(Springer, 2006) Bedel, D.; Durmus-Altun, G.; Ergulen, A.; Berkarda, S.[Abstract Not Available]
